Applied DNA Sciences, Inc. (APDN)
NASDAQ: APDN · IEX Real-Time Price · USD
0.440
-0.105 (-19.25%)
At close: Jul 2, 2024, 4:00 PM
0.457
+0.017 (3.79%)
After-hours: Jul 2, 2024, 7:58 PM EDT
Applied DNA Sciences Revenue
Applied DNA Sciences had revenue of $5.52M in the twelve months ending March 31, 2024, down -68.52% year-over-year. Revenue in the quarter ending March 31, 2024 was $929.63K, a -78.91% decrease year-over-year. In the fiscal year ending September 30, 2023, Applied DNA Sciences had annual revenue of $13.37M, a decrease of -26.43%.
Revenue (ttm)
$5.52M
Revenue Growth
-68.52%
P/S Ratio
0.08
Revenue / Employee
$106,113
Employees
52
Market Cap
433.38K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 13.37M | -4.80M | -26.43% |
Sep 30, 2022 | 18.17M | 9.14M | 101.25% |
Sep 30, 2021 | 9.03M | 7.10M | 367.40% |
Sep 30, 2020 | 1.93M | -3.46M | -64.16% |
Sep 30, 2019 | 5.39M | 1.49M | 38.06% |
Sep 30, 2018 | 3.90M | -847.92K | -17.85% |
Sep 30, 2017 | 4.75M | 564.83K | 13.49% |
Sep 30, 2016 | 4.19M | -4.82M | -53.53% |
Sep 30, 2015 | 9.01M | 6.29M | 231.05% |
Sep 30, 2014 | 2.72M | 685.00K | 33.64% |
Sep 30, 2013 | 2.04M | 181.53K | 9.79% |
Sep 30, 2012 | 1.85M | 885.85K | 91.43% |
Sep 30, 2011 | 968.85K | 449.00K | 86.37% |
Sep 30, 2010 | 519.84K | 224.68K | 76.12% |
Sep 30, 2009 | 295.16K | -577.85K | -66.19% |
Sep 30, 2008 | 873.01K | 751.09K | 616.05% |
Sep 30, 2007 | 121.92K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPDN News
- 12 days ago - Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics - Accesswire
- 14 days ago - Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing - Accesswire
- 19 days ago - Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health - Accesswire
- 22 days ago - Time to Play 5 Top-Ranked Stocks With Rising P/E? - Benzinga
- 27 days ago - Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform - Accesswire
- 7 weeks ago - Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML - Accesswire
- 7 weeks ago - Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results - Accesswire
- 7 weeks ago - Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Accesswire